🇺🇸 FK949E in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 2
Most-reported reactions
- Hepatitis Acute — 1 report (50%)
- Mania — 1 report (50%)
Other Musculoskeletal / Endocrinology approved in United States
Frequently asked questions
Is FK949E approved in United States?
FK949E does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for FK949E in United States?
Astellas Pharma Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.